CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE

CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE

The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HE, HONGYAN, TAN, HEOW, LAW, BRIAN, LU, DANIEL, WONG, ANGELINA SAU MAN, SOMANATH, PRIYANKA, PALMER, JAMES T, LIN, NAN-HORNG, KINOSHITA, TAISEI, BUTLER, THOMAS, JAING, SIYI
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data. La présente invention concerne des formes cristallines de N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-D]pyrimidine-6-yl]phényl]-4-[[3(R)-[(1-oxo-2-propène-1-yl)amino]-1-pipéridinyl]méthyl]-2-pyridinecarboxamide (formule (I). Le composé (I) est un inhibiteur irréversible de ménine-MLL pour une utilisation dans le traitement par ex. du cancer, par ex. d'un lymphome, d'une leucémie et de maladies auto-immunes.L'invention concerne également la caractérisation de formes cristallines par ex. par XRPD, FTIR, DSC et TGA ainsi que des données pharmacologiques.